Explore this research category across breast cancer datasets
| RNA Name | Mechanism of Action | Effect on Cancer | Cancer Type | Reference |
|---|---|---|---|---|
|
LncFASA
lncRNA |
Increases lipid peroxidation and disrupts ROS homeostasis by inhibiting PRDX1 activity | Impaired growth of triple-negative breast cancer; high expression indicates better survival | Breast Cancer |
PubMed
Reference PMID: 37955780 |
|
PTPRG-AS1
lncRNA |
Inhibits ferroptosis via miR-376c-3p/SLC7A11 axis | Promotes triple-negative breast cancer development | Breast Cancer |
PubMed
Reference PMID: 38318853 |
|
HCP5
lncRNA |
Regulating GPX4 expression and lipid ROS level | Inhibits ferroptosis | Breast Cancer |
PubMed
Reference PMID: 36980766 |
|
LINC00460
lncRNA |
LINC00460 knockdown suppressed proliferation of breast cancer cells and promoted ferroptosis | Inhibits cancer ferroptosis | Breast Cancer |
PubMed
Reference PMID: 36938678 |
|
H19
lncRNA |
H19 regulates ferroptosis via autophagy. Metformin-induced ferroptosis is mediated by inhibiting autophagy through H19; knockdown of H19 enhances lipid-ROS accumulation and ferroptosis. | H19 is oncogenic in breast cancer – its overexpression promotes tumorigenesis. In BC models H19 overexpression increases proliferation and invasion. | Breast Cancer |
PubMed
Reference PMID: 34644456 |
|
NEAT1
lncRNA |
NEAT1 acts as a ceRNA to promote ferroptosis. It sponges miR-362-3p to upregulate MIOX, which raises ROS and depletes GSH, thereby enhancing erastin/RSL3-induced ferroptosis. | NEAT1 is pro-tumorigenic in BC. It promotes cell proliferation, migration, invasion, and metastasis; knockdown of NEAT1 suppresses these malignant phenotypes. | Breast Cancer |
PubMed
Reference PMID: 35338333 |
|
NEAT1
lncRNA |
NEAT1 acts as a ceRNA to promote ferroptosis. It sponges miR-362-3p to upregulate MIOX, which raises ROS and depletes GSH, thereby enhancing erastin/RSL3-induced ferroptosis. | NEAT1 is pro-tumorigenic in BC. It promotes cell proliferation, migration, invasion, and metastasis; knockdown of NEAT1 suppresses these malignant phenotypes. | Breast Cancer |
PubMed
Reference PMID: 32801860 |
|
KCNQ1OT1
lncRNA |
KCNQ1OT1 epigenetically inhibits ferroptosis. It recruits the methyltransferase MLL4 to the TRABD promoter, increasing H3K4 methylation and TRABD expression. Inhibition of KCNQ1OT1 (e.g. by ZC3H13-mediated m6A) restores ferroptosis. | KCNQ1OT1 drives chemoresistance and growth in TNBC. Its activation of the TRABD axis promotes doxorubicin resistance; silencing KCNQ1OT1 (by ZC3H13) suppresses proliferation and induces ferroptosis in TNBC. | Breast Cancer |
PubMed
Reference PMID: 40000487 |
|
miR-153
miRNA |
Reduces cell ferroptosis via circ_0000643/miR-153/SLC7A11 axis | Inhibits ferroptosis and promotes progression | Breast Cancer |
PubMed
Reference PMID: 37591453 |
|
miR-335-5p
miRNA |
Regulates GPX4 via Sp1 transcription factor | Induces ferroptosis and inhibits progression | Breast Cancer |
PubMed
Reference PMID: 38866351 |